Kymera Therapeutics Inc (KYMR) is expecting 47.84% growth in the next quarter: What can investors do to maximize their returns?

Kymera Therapeutics Inc (NASDAQ: KYMR) on Tuesday, plunged -4.52% from the previous trading day, before settling in for the closing price of $39.42. Within the past 52 weeks, KYMR’s price has moved between $9.60 and $45.31.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Healthcare Sector giant saw their annual sales surged by 241.22% over the last five years. The company achieved an average annual earnings per share of -19.14%. With a float of $54.16 million, this company’s outstanding shares have now reached $55.59 million.

The firm has a total of 187 workers. Let’s measure their productivity.

Kymera Therapeutics Inc (KYMR) Insider Activity

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kymera Therapeutics Inc is 11.38%, while institutional ownership is 90.16%. The most recent insider transaction that took place on Mar 15 ’24, was worth 2,903,336. In this transaction Director of this company sold 71,764 shares at a rate of $40.46, taking the stock ownership to the 806,697 shares. Before that another transaction happened on Mar 14 ’24, when Company’s Director sold 55,779 for $39.98, making the entire transaction worth $2,229,927. This insider now owns 819,151 shares in total.

Kymera Therapeutics Inc (KYMR) Earnings and Forecasts

As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.25 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.4) by $0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -19.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.90% during the next five years compared to -39.18% drop over the previous five years of trading.

Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators

Kymera Therapeutics Inc (KYMR) is currently performing well based on its current performance indicators. A quick ratio of 4.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.27.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.52, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -3.35 in one year’s time.

Technical Analysis of Kymera Therapeutics Inc (KYMR)

Analysing the last 5-days average volume posted by the [Kymera Therapeutics Inc, KYMR], we can find that recorded value of 0.53 million was lower than the volume posted last year of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 32.10%. Additionally, its Average True Range was 1.94.

During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 75.62%, which indicates a significant increase from 13.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.08% in the past 14 days, which was lower than the 71.81% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $38.13, while its 200-day Moving Average is $24.58. Now, the first resistance to watch is $38.61. This is followed by the second major resistance level at $39.59. The third major resistance level sits at $40.52. If the price goes on to break the first support level at $36.71, it is likely to go to the next support level at $35.78. Should the price break the second support level, the third support level stands at $34.81.

Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats

Market capitalization of the company is 2.30 billion based on 61,112K outstanding shares. Right now, sales total 78,590 K and income totals -146,960 K. The company made 47,890 K in profit during its latest quarter, and -14,370 K in sales during its previous quarter.